Autopsy report · NCT03029585

Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer

“Business reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 2 years 7 months before it stopped.
• 10 participants enrolled.
• Results were posted on the registry 1 year 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

NanOlogy, LLC

Sponsor type

Industry

Conditions

Ovarian Carcinoma

Interventions

NanoPac® 100 mg/m2; NanoPac® 200 mg/m2; NanoPac® 300 mg/m2; NanoPac® 400 mg/m2; Standard of Care Intravenous Chemotherapy

Participants

10

Sites

7

Countries

United States

Trials that died the same way

• A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
  “Business Reason” (94% match in meaning)
• Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
  “Financial/Business Reasons” (88% match in meaning)
• First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
  “Business/Commercial Reasons” (87% match in meaning)
• Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation
  “Organizational reasons” (85% match in meaning)
• Incisionless Treatment for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass
  “For business reasons” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.